A comparison of efficacy and safety of an ezetimibe/simvastatin combination
compared with other intensified lipid-lowering treatment strategies in diabetic
patients with symptomatic cardiovascular disease.
Author(s): Rosen JB(1), Jimenez JG, Pirags V, Vides H, Hanson ME, Massaad R, McPeters G,
Brudi P, Triscari J.
Affiliation(s): Author information:
(1)Clinical Research of South Florida, Coral Gables, FL 33134, USA. JBRcrsf@aol.com
Publication date & source: 2013, Diab Vasc Dis Res. , 10(3):277-86
The low-density lipoprotein cholesterol (LDL-C) lowering efficacy of switching to
ezetimibe/simvastatin (EZ/S) 10/20 mg versus doubling the run-in statin dose (to
simvastatin 40 mg or atorvastatin 20 mg) or switching to rosuvastatin 10 mg in
subjects with cardiovascular disease (CVD) and diabetes was assessed. Endpoints
included percentage change in LDL-C and percentage of patients achieving LDL-C
<70 mg/dL. Significantly greater reductions in LDL-C occurred when switching to
EZ/S versus statin doubling in the overall population and in subjects treated
with simvastatin 20 mg or atorvastatin 10 mg (all p < 0.001). The LDL-C reduction
was numerically greater when switching to EZ/S versus switching to rosuvastatin
(p = 0.060). Significantly more subjects reached LDL-C <70 mg/dL with EZ/S
(54.5%) versus statin doubling (27.0%) or rosuvastatin (42.5%) in the overall
population (all p < 0.001) and within each stratum (all p < 0.001). Switching to
EZ/S provided significantly greater reductions in LDL-C versus statin doubling
and significantly greater achievement of LDL-C targets versus statin doubling or
switching to rosuvastatin.
|